Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Eton Pharmaceuticals, Inc. (ETON : NSDQ)
 
 • Company Description   
Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.

Number of Employees: 17

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.26 Daily Weekly Monthly
20 Day Moving Average: 56,800 shares
Shares Outstanding: 25.22 (millions)
Market Capitalization: $82.23 (millions)
Beta: 1.42
52 Week High: $8.90
52 Week Low: $2.76
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.32% -4.64%
12 Week -10.44% -1.55%
Year To Date -24.01% -9.14%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
21925 W. FIELD PARKWAY SUITE 235
-
DEER PARK,IL 60010
USA		 ph: 847-787-7361
fax: -		 investorrelations@etonpharma.com http://www.etonpharma.com
 
 • General Corporate Information   
Officers
Sean E. Brynjelsen - Chief Executive Officer;President and Director
W. Wilson Troutman - Chief Financial Officer; Treasurer and Secretary
Jennifer M. Adams - Director
Charles J. Casamento - Director
Paul V. Maier - Director

Peer Information
Eton Pharmaceuticals, Inc. (CORR.)
Eton Pharmaceuticals, Inc. (RSPI)
Eton Pharmaceuticals, Inc. (CGXP)
Eton Pharmaceuticals, Inc. (BGEN)
Eton Pharmaceuticals, Inc. (GTBP)
Eton Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29772L108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 25.22
Most Recent Split Date: (:1)
Beta: 1.42
Market Capitalization: $82.23 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.05 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.05 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.14
Price/Cash Flow: -
Price / Sales: 6.79
EPS Growth
vs. Year Ago Period: -210.53%
vs. Previous Quarter: -625.00%
Sales Growth
vs. Year Ago Period: -81.71%
vs. Previous Quarter: -64.29%
ROE
03/31/22 - -73.59
12/31/21 - -10.35
09/30/21 - -58.04
ROA
03/31/22 - -46.28
12/31/21 - -6.79
09/30/21 - -37.47
Current Ratio
03/31/22 - 5.39
12/31/21 - 5.18
09/30/21 - 4.83
Quick Ratio
03/31/22 - 5.24
12/31/21 - 5.06
09/30/21 - 4.76
Operating Margin
03/31/22 - -102.39
12/31/21 - -8.95
09/30/21 - -67.52
Net Margin
03/31/22 - -102.39
12/31/21 - -8.95
09/30/21 - -67.52
Pre-Tax Margin
03/31/22 - -102.39
12/31/21 - -8.95
09/30/21 - -67.52
Book Value
03/31/22 - 0.53
12/31/21 - 0.72
09/30/21 - 0.64
Inventory Turnover
03/31/22 - 2.66
12/31/21 - 3.02
09/30/21 - 2.54
Debt-to-Equity
03/31/22 - 0.47
12/31/21 - 0.30
09/30/21 - 0.35
Debt-to-Capital
03/31/22 - 32.11
12/31/21 - 22.99
09/30/21 - 26.17
 

Powered by Zacks Investment Research ©